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Imaging approaches are an essential tool for following up over time representative
parameters of in vivo models, providing useful information in pharmacological studies.
Main advantages of optical imaging approaches compared to other imaging methods
are their safety, straight-forward use and cost-effectiveness. A main drawback, however,
is having to deal with the presence of high scattering and high absorption in living
tissues. Depending on how these issues are addressed, three different modalities can
be differentiated: planar imaging (including fluorescence and bioluminescence in vivo
imaging), optical tomography, and optoacoustic approaches. In this review we describe
the latest advances in optical in vivo imaging with pharmacological applications, with
special focus on the development of new optical imaging probes in order to overcome
the strong absorption introduced by different tissue components, especially hemoglobin,
and the development of multimodal imaging systems in order to overcome the resolution
limitations imposed by scattering.
Keywords: bioluminescence, planar fluorescence imaging, fluorescence molecular tomography, optoacoustics,
multispectral optoacoustic tomography, multispectral imaging, hybrid systems, data processing
Introduction
Whole-body optical in vivo imaging approaches are valuable tools that enable the study of animal
models of human diseases, reducing the number of animals required for experimentation and
providing essential information in pharmacological studies. Depending on the physical principle
providing image contrast, we find techniques based on light generation, such as bioluminescence or
fluorescence imaging, or based on light absorption, such as optoacoustics. All these methodologies
enable in vivo imaging of molecular and cellular processes with high sensitivity and have gained
great popularity over the past decade mainly because of their safe and straightforward use due to the
employment of non-ionizing wavelengths, and their cost-effectiveness compared with other imaging
technologies (such as positron emission tomography, PET, or magnetic resonance imaging, MRI;
Ntziachristos et al., 2007; Stuker et al., 2011b).
On the other hand, one of the main problems of optical in vivo technologies is dealing with the
scattering and absorption properties of tissue (Boas et al., 2011; Ripoll, 2012): scattering is responsible
for the loss of light directionality (and therefore a loss in resolution by consequently blurring the
image), while the presence of high absorbers (such as melanin and blood) results in a reduction of
light intensity (decreasing the signal to noise ratio dramatically in the visible range; Ripoll, 2012).
The most effective way to overcome the loss of signal intensity due to absorption is to employ
excitation and emission wavelengths in the near-infrared optical imaging window (between 700 and
900 nm, approximately), where themain tissue constituents (hemoglobin,melanin, water, and lipids)
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absorb the least (Ntziachristos et al., 2005; Jacques, 2013). On
the other hand, if one wishes to account for the effects of high
scattering in light propagation within tissues in order to obtain
a 3D image or quantitative information (note that location,
probe concentration, and probe size are strongly interdependent),
one needs to introduce a physical model of light propagation
within complex media such as a living organism. Once this
model is in place, a numerical inversion of this model (what
is termed, “solving the inverse problem”) is needed in order to
obtain a 3D image providing the spatial distribution of probe
concentration. Depending on the algorithm we use to reconstruct
an image we will be able to recover probe size, position and
concentration with varying accuracy. How this issue is addressed
clearly distinguishes the different imaging approaches in optical
in vivo imaging into the following three categories: (1) planar
optical imaging, (2) optical tomography, and (3) optoacoustic
tomography.
In this review we discuss the latest advances of optical in
vivo imaging as a tool in pharmaceutical studies, addressing
the different approaches that are being developed in order to
overcome the strong absorption introduced by hemoglobin and
the ill-posedness introduced by scattering, either through the
use of multimodal imaging or photoacoustic tomography, or by
developing new probes or proteins more adequate for in vivo
imaging in deep tissues.
Planar Optical Imaging
Planar optical imaging techniques are by far the most common,
mainly due to their simplicity of use and low cost. Two planar
imaging modalities are available, depending on the light source
generation: Bioluminescence and Fluorescence. In both cases a
high sensitivity camera (CCDmainly) coupled to a high numerical
aperture camera objective takes a single long exposure image, in
the case of fluorescence using appropriate band-pass filters. In
what follows we detail recent advances and applications in both
modalities.
Bioluminescence In Vivo Imaging
Bioluminescence imaging is based on the oxidation of a
substrate (luciferin) mediated by an enzyme (luciferase), being
themost commonly used the luciferase originated from the North
American firefly (Photinus pyralis). The firefly luciferase requires
ATP and magnesium to catalyze the reaction that leads to the
emission of light, which ranges from 530 to 640 nm, depending
amongst other factors on the pH, polarity of the solvent, and the
microenvironment of the enzyme (Li et al., 2013). Note how this
emission falls within the portion of the visible spectrum where
hemoglobin is strongly absorbing.
Since the firefly luciferase was cloned (de Wet et al., 1985),
the luc gene has extensively been used in gene regulation studies.
Bioluminescent probes have also been engineered in order to
detect specific enzymatic activities. These probes are designed in
such a way that the luciferin is “caged” and this conjugate has to be
cleaved by an enzymatic activity (i.e., proteases such as caspases).
Once cleaved, the luciferin can be oxidized by the luciferase and
the signal is released (Li et al., 2013).
Techniques based on bioluminescence detection have largely
been used for molecular biology assays in laboratories worldwide.
Accordingly, bioluminescence has also been a reference method
for in vivo imaging. Its main advantage is the absence of
background signal (the commonly used cell or animal models
do not express luciferase and therefore there is no “auto-
bioluminescence”), which leads to a high specificity of the
detected signals and an elevated signal-to-noise ratio. This has
resulted in an impressive expansion of bioluminescence in vivo
imaging applications for studies in cancer biology, inflammation,
and infection, amongst others (Edinger et al., 2002; Andreu et al.,
2010; Luker and Luker, 2011; Luwor et al., 2015). However,
researchers using bioluminescence in vivo imaging have to deal
with problems derived from the complexity of the luciferase-
luciferin reaction and the effects of light propagation in living
tissues. Regarding the luciferase-luciferin reaction, both substrate
and co-factors (ATP, oxygen and magnesium) are required for
the reaction to take place and therefore the limitation of any
of them may result in altered readouts that are not a real
representation of luciferase activity (Sadikot and Blackwell, 2005).
There have also been significant efforts toward the development
of bioluminescence tomography (BLT) approaches, requiring the
prior knowledge of one of the parameters or the number of sources
in order to produce a 3D image (Liu et al., 2010).
Fluorescence In Vivo Imaging
After a fluorescent agent is excitedwith a light source, fluorescence
is emitted isotropically as a consequence of a radiative transition
from an excited singlet state to a singlet state of lower energy
(typically the ground state) following Stoke’s Law (Sauer et al.,
2011). Even though fluorescence has been extensively used in
microscopy for over a century to study molecular and cellular
processes (Masters, 2009), it has not been until this past decade
that its use for in vivo small animal imaging became significant
(Mahmood et al., 1999;Weissleder et al., 1999; Ntziachristos et al.,
2005). The high sensitivity offered by this technique and the latest
advances in fluorescence labeling have also promoted its relatively
recent incursion in non-invasive in vivo imaging. Both planar and
three-dimensional fluorescence imaging methods in vivo are now
commonly used in pre-clinical research.
In order to acquire a fluorescence image, either as part of a
tomographic data set or a single planar image, one requires an
excitation source as close as possible to the excitation maximum
of the fluorophore being used, if possible within the near infrared
optical imaging window. The use of this excitation wavelength,
however, will not only excite specifically the fluorophore but
will generate non-specific fluorescence from several components
present in tissue, generating what is termed “auto-fluorescence,”
reducing the signal to background ratio (i.e., the contrast in the
image). One way to reduce this problem is performing several
spectral measurements with different excitation/emission pairs
and unmixing the specific signal of the fluorophore from the
un-specific signal of the surrounding tissue (Xu and Rice, 2009).
With respect to recent pharmacological studies, Zhang et al.
(2015b) make use of planar fluorescence molecular imaging to
monitor therapy in murine models of Alzheimer’s disease. In
particular, the authors verify the feasibility of using CRANAD-3
Frontiers in Pharmacology | www.frontiersin.org September 2015 | Volume 6 | Article 1892
Arranz and Ripoll Advances in optical imaging in vivo
FIGURE 1 | In vivo monitoring of therapeutic effect of drug treatment in Alzheimer’s disease. Application of CRANAD-3 for monitoring therapeutic effects of
drug treatments. (A) In vivo imaging of APP/PS1 mice with CRANAD-3 before and after treatment with the BACE-1 inhibitor LY2811376. (B) Quantitative analysis of
the imaging in A (n = 4). (C) Representative images of 4-month-old APP/PS1 mice after 6 months of treatment with CRANAD-17. (Left) Age-matched WT mouse.
(Center) Control APP/PS1 mouse. (Right) CRANAD-17—treated APP/PS1 mouse. Note that the NIRF signal from the CRANAD-17—treated APP/PS1 mouse (Right)
is lower than the signal from the non-treated control APP/PS1 mouse (Center). (D) Quantitative analysis of the imaging in C (n = 5). (E) ELISA analysis of total Ab40
from brain extracts. (F) Analysis of plaque counting. (G) Representative histological staining with thioflavin S. (Left) CRANAD-17—treated mouse. (Right) Control.
*P < 0.05, **P < 0.01, ***P < 0.005. From Zhang et al. (2015b).
for monitoring therapy, and use it to monitor the therapeutic
effect of CRANAD-17, a curcumin analog for inhibition of Ab
cross-linking (see Figure 1).
Diffuse Optical Tomography and
Fluorescence Molecular Tomography
In order to account for the effect of scattering when imaging
tissues with light, diffuse optical tomography (DOT) was
developed, based on scanning a point source over the sample
and measuring the intensity of the diffuse light either by fibers
or with a camera focused onto the surface (see Arridge, 1999,
for a review on this subject). With its first applications being
targeted toward breast cancer (see, for exampleNtziachristos et al.,
2000) its use in small animal imaging came with the development
of fluorescence molecular tomography, first published in 2002
(Ntziachristos et al., 2002), in the context of molecular imaging
by employing an activatable probe to image protease activity in an
in vivo mouse model of glioblastoma. Since this first publication
in 2002 there have been several developments and applications,
mainly in tumor biology (Ntziachristos et al., 2004; Deliolanis
et al., 2006; Montet et al., 2007; Kossodo et al., 2010; Hensley et al.,
2012) and inflammation studies (Martin et al., 2008; Kang et al.,
2014; Thomas et al., 2015), amongst others.
Apart from suffering from auto-fluorescence in a manner
similar to planar fluorescence imaging, DOT and FMT provide
no anatomical information and therefore benefit from its
combination with measurements provided by other imaging
systems such as X-ray computed tomography (CT) or MRI, issue
which we will discuss at the end of this review. Additionally,
the prior knowledge of anatomical features and optical properties
significantly improves image quality and quantitation, as will be
discussed later.
Optoacoustic In Vivo Imaging
Being based on the emission of sound after a transient increase
in volume due to light absorption, the photoacoustic effect may
be used to image in 3D the location and relative concentration
of fluorescence probes using advanced acoustic transducers and
light sources. Termed Optoacoustic or Photoacoustic imaging, it
circumvents the “blurring” caused by scattering on the visible
wavelengths by measuring the acoustic wave generated, which
suffers several orders of magnitude less scattering, resulting in
an increased penetration depth with no significant loss of signal
to noise. In order for this approach to be implemented and
transient volume changes generated, we need to use pulsed
lasers and then record the ultrasound wave generated by the
localized absorption of this pulse of light by the tissue. Recording
this ultrasound wave at several locations simultaneously, we
may make use of tomographic methods to recover a 3D image
(Wang et al., 2003). When multispectral methods are used, such
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FIGURE 2 | Pharmacokinetic in vivo imaging using MSOT. (A) Time series of images visualizing the biodistribution of IRdye800 in green on logarithmic scale
overlaid on the vasculature. Both channels are the result of spectral unmixing. (B) Cryoslice image after approximately 15 min with overlaid fluorescence as a
verification of the MSOT results. (C) A comparison of fluorescence distribution in the kidneys of mice sacrificed after approximately 2 min 30 s after injection and
15 min after injection. Note the changes in distribution similar to the time series shown in (A). (D) Temporal evolution of signal (each normalized to their smoothed
maxima) in the regions of interest highlighted in the rightmost image, orange showing a region in the renal cortex that displays early and steep signal pickup and black
indicating a region in the renal pelvis where probe accumulation is delayed and has a smoother profile. Time points of the images in (A) are marked using vertical
lines. From Taruttis et al. (2012).
as in multispectral optoacoustic tomography (MSOT), different
fluorophores may be separated and their relative concentration
quantified (Laufer et al., 2007; Ma et al., 2009; Tzoumas et al.,
2014), underlying the use of MSOT for quantitative and highly
specific in vivo imaging. Additionally, since hemoglobin is a
strong absorber, optoacoustic tomography may also be used for
resolving vascular structures and quantifying oxygen saturation
and blood volume (Lao et al., 2008; Hu and Wang, 2010).
The high resolution of MSOT—approximately 100 mm and in
some cases even better [40 mm resolution was shown in Ma
et al. (2009)], good anatomical information, and quantitative 3D
images are the reason why this approach is becoming widespread
in pharmacological studies.
One application of MSOT to pharmacological studies which
show extremely high impact is the use of MSOT to follow
pharmacokinetics in vivo (Kossodo et al., 2010; Razansky et al.,
2011, 2012; Bednar and Ntziachristos, 2012; Taruttis et al., 2012).
Figure 2 shows an example of the potential ofMSOT, where a time
series of images visualizing in vivo the biodistribution of IRdye800
and vasculature are shown. This study shows how the spatially
localized temporal evolution of drug delivery may be imaged in
real time.
One of the drawbacks of optoacoustic tomography is its lower
sensitivity when compared to pure fluorescence measurements
and the difficulty of imaging in organs that present high acoustic
contrast or high impedance mismatch, such as the lungs. Another
drawback is that the signal generated is proportional to the light
intensity that has been absorbed locally and thus decreases for
deeper tissues. Even though the lack of knowledge on the precise
light distribution within the subject precludes this technique from
being fully quantitative, the development of advanced inverse
methods and imaging approaches are constantly improving the
quantitative nature of MSOT (Razansky et al., 2011).
Latest Advances to Improve Quantification
and Resolution
Once we have covered the main optical imaging approaches,
we now will present the most recent advances to improve these
imaging techniques either by changing the emission spectra of the
probes or by including anatomical information and thus reducing
the ill-posed nature of the inverse problem.
Avoiding Absorption in Living Tissues: Moving
Toward the Near Infra-Red
As mentioned previously, working with wavelengths in the near
infra-red (NIR), in particular in the 700–900 nm window,
reduces the amount of light absorbed in tissues by 3 orders of
magnitude when compared to the visible spectrum. Due mainly
to hemoglobin absorption and considering that the emission peak
of the native firefly luciferase is in the range of 562 nm, its
detection is mainly limited to the surface. Great efforts have
been focused on obtainingmutated versions of luciferase enzymes
leading to red-shifted emission wavelengths, with emission peaks
above 600 nm (Branchini et al., 2010a; Stepanyuk et al., 2010;
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Mezzanotte et al., 2011; Wang et al., 2013). In order to obtain
emitted light with longer-wavelengths, considerable effort has
also been devoted to the development of analogs of the substrate
(luciferin), such as aminoluciferins (Mofford et al., 2014) or
selenium analogs (Conley et al., 2012). Other developments
have been bioluminescence resonance energy transfer (BRET)
conjugates, consisting on using the emitted bioluminescence light
as excitation for fluorescentmolecules. The use of these conjugates
results in a final emitted light above 700 nm (Branchini et al.,
2010b), although it has been discussed that they may alter the
cellular uptake properties of the substrate (Conley et al., 2012).
In the case of fluorescence, an impressive development of
new NIR fluorescent agents has taken place in recent years with
excitation maxima above 650 nm, allowing the use of excitation
sources and emission spectra within the optical window of the
spectrum, where blood absorption is reduced to a minimum
(Ntziachristos et al., 2005; Jacques, 2013). Researchers can now
benefit from a wide portfolio of near infra-red fluorescent
(NIRF) probes designed to be non-targeted (non-specific used
for imaging of perfusion or vascular leakage), targeted (such
as fluorescent-conjugated antibodies, which recognize and bind
specific ligands), or activatable (the fluorescent signal is quenched
unless a specific enzymatic activity cleaves the probe). Moreover,
different approaches have been followed to obtain NIRF proteins,
reaching excitation maxima above 670 nm (Shcherbo et al.,
2007; Shu et al., 2009; Filonov et al., 2012). Constructs for the
expression of these proteins and recently developed transgenic
mice (Diéguez-Hurtado et al., 2011; Tran et al., 2014) provide
an excellent tool for in vivo imaging applied to biomedical and
pharmaceutical studies.
With respect to optoacoustics, all advances in fluorescent
probes are directly compatible with this methodology, since
probes with high quantum yield by definition present high
absorption properties. Additionally, optoacoustic imaging
methods are also benefiting from new engineered acoustic probes
based on metallic nanoparticles (mainly gold) which exhibit high
absorption profiles (Bao et al., 2013; Vonnemann et al., 2014).
Finally, a very interesting and promising new development is
the use of Cherenkov excited luminescence imaging (CELSI) to
improve resolution and partially avoid the effect of absorption
while exciting the fluorophores (Zhang et al., 2012, 2013b, 2015a).
This approach makes use of Cherenkov emitted NIR light from
collimated ionizing radiation generated in a linear accelerator
(LINAC), a technique which could potentially be applied for
imaging fluorescent markers deep in tissue with high resolution.
Hybrid Systems
The combination of optical imaging modalities with structural
imaging methods such as X-ray CT or MRI allows obtaining
anatomical information that can be used as prior data on
the reconstruction algorithm to improve both resolution and
sensitivity (Ale et al., 2012).
For example, FMT-MRI hybrid systems have been developed
and used to analyze protease activity and tumor morphology in
mouse tumor models (Davis et al., 2010; Stuker et al., 2011a)
or metalloproteinase activity in mouse models of atherosclerosis
(Li et al., 2014). FMT-XCT hybrid systems are also examples
TABLE 1 | Comparison of different imaging modalities.
Technique Resolution Throughput Pharmacokinetics 3D Info
Bioluminescence >5 mm* High No No
Planar fluorescence >5 mm* High No No
FMT 1–2 mm Medium No Yes
FMT/XCT 1 mm Low No Yes
MSOT 0.1 mm Low Yes Yes
*Resolution depends on depth location.
where we can make use of anatomical priors obtained from the
geometric information provided by the XCT measurements in
order to improve the 3D reconstruction of the fluorescence signal
(Ale et al., 2012; Zhang et al., 2013a, 2014).
The technical complexity of these hybrid systems (for example,
due to crosstalk between optical and MRI imaging) has led to the
use of adapted animal holders which are compatible with different
modality systems enabling sequential imaging (McCann et al.,
2009).
Conclusions and Future Outlook
A wide range of optical imaging modalities are available for in
vivo imaging in small animals, representing an essential tool in
pharmacological studies. Each modality, however, presents its
own drawbacks, mainly due to the effects of absorption and
scattering of light propagation in living tissues. As shown in
Table 1, the selection of a techniquewill dependon themodel used
and the information that we want to obtain. For example, if high-
throughput imaging is required, planar imaging approaches will
be useful, with the consequence that no quantitative information
or depth location may be inferred (see Table 1). If quantitative
imaging and probe location is important, tomography is needed
and FMT and similar approaches are a good option, reaching
their full potential when combined with an anatomical imaging
modality such asMRI or X-ray CT. As a quickly growingmodality,
optoacoustic tomography and in particular MSOT shows great
potential, so far offering the best imaging resolution, but with
the problems associated with ultrasound imaging such as high
impedance mismatch in some organs such as the lungs and the
need for a matching gels.
We believe that as more specific near infrared fluorescent
probes and proteins with distinct spectral features, and
specific nanoparticles for high and specific optoacoustic
signal generation are generated there will be further improvement
of the performance of the technologies covered in this review,
opening opportunities for new applications. The combination
of several imaging modalities, specifically if they include optical
imaging approaches, will ensure the sensitivity and specificity
that optical probes uniquely offer may reach their full potential as
imaging agents for 3D quantitative imaging in vivo.
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